Teladoc Health Reports Second Quarter 2019 Results

July 31, 2019

Download this Press Release (PDF 675 KB)

Year-over-year Q2 revenue grows 38% to $130.3 million and total visits increase 70% to 908,000

Year-over-year first half revenue grows 41% to $258.8 million and total visits increase 73% to 1,971,000

Issues 2019 third-quarter guidance and updates full-year expectations

PURCHASE, NY, July 31, 2019 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported financial results for the second quarter ending June 30, 2019.

“The second quarter punctuated a strong first half of the year for Teladoc Health. Our robust engagement science strategies have allowed us to capitalize on the macro tailwinds we’re seeing globally to drive solid results across all of our markets and clinical specialties,” said Jason Gorevic, chief executive officer, Teladoc Health. “We built out our senior leadership team with two important additions during the quarter, and we made meaningful progress towards realizing the long-term benefits of our diversified growth strategy. The persistent strength in our visit volume and our accelerating sales pipeline serves as yet another affirmation of the broader acceptance and prevalence of virtual care in the healthcare system today.”

Financial Highlights for the Second Quarter and Six Months Ended June 30, 2019

Revenue
($ thousands)
	Quarter Ended				Year over Year		Six Months Ended				Year over Year
	June 30,				Growth		June 30,				Growth
	2019		2018				2019		2018
Subscription Access Fees Revenue
U.S.	$	85,530	$	65,066	31	%	$	166,509	$	126,086	32	%
International		25,711		14,731	75	%		50,686		25,440	99	%
Total		111,241		79,797	39	%		217,195		151,526	43	%

Visit Fee Revenue
U.S. Paid Visits		15,083		11,795	28	%		33,331		26,004	28	%
U.S. Visit Fee Only		3,546		2,710	31	%		7,667		6,249	23	%
International Paid Visits		406		258	57	%		656		425	54	%
Total		19,035		14,763	29	%		41,654		32,678	27	%

Total Revenue*	$	130,276	$	94,560	38	%	$	258,849	$	184,204	41	%

*Organic second-quarter 2019 revenue, excluding Advance Medical, increased by 24 percent year over year.
Organic six months ended 2019 revenue, excluding Advance Medical, increased by 23 percent year over year.


Membership & Visit Fee Only Access
(millions)
	Quarter Ended		Year over Year
	June 30,		Growth
	2019	2018
Total U.S. Paid Membership*	26.8	22.5	19.0	%

Total U.S. Visit Fee Only Access	9.7	9.6	0.9	%


Visits
(thousands)
	Quarter Ended				Year over Year		Six Months Ended				Year over Year
	June 30,				Growth		June 30,				Growth
	2019		2018				2019		2018
Paid Visits from U.S. Paid Membership	291		218		33	%	656		516		27	%
Percent of Paid Visits from U.S. Paid Membership	48	%	50	%	(5	)%	49	%	52	%	(5	)%
Visits Included from U.S. Paid Membership	319		218		46	%	672		474		42	%

Total Visits from U.S. Paid Membership	610		436		40	%	1,328		990		34	%

U.S. Visit Fee Only	54		37		47	%	116		88		33	%

International Visits	244		60		309	%	527		60		771	%
Total Visits	908		533		70	%	1,971		1,138		73	%

Net loss was $(29.3) million for the second quarter 2019 compared to $(25.1) million for the second quarter 2018.
Net loss per basic and diluted share was $(0.41) for the second quarter 2019 compared to $(0.40) for the second quarter 2018.
Gross margin was 68.0 percent for the second quarter 2019 compared to 70.7 percent for the second quarter 2018.
EBITDA was $(12.2) million for the second quarter 2019 compared to $(10.1) million for the second quarter 2018.
Adjusted EBITDA was a positive $6.3 million for the second quarter 2019 compared to $2.7 million for the second quarter 2018.

A reconciliation of generally accepted accounting principles (“GAAP”) in the United States to non-GAAP results has been provided in this press release in the accompanying tables. An explanation of these measures is also included below under the heading “Non-GAAP Financial Measures”.

Financial Outlook
Teladoc Health provides guidance based on current market conditions and expectations.

For the third-quarter 2019, we expect:

Total revenue to be in the range of $135 million to $138 million.
EBITDA loss to be in the range of $(10.5) million to $(12.5) million.
Adjusted EBITDA to be in the range of $7 million to $9 million.
Total U.S. paid membership to be in the range of 28.5 million to 29.5 million and visit-fee-only access to be available to approximately 10 million individuals.
Total visits to be between 800,000 and 900,000.
Net loss per share, based on 72.3 million weighted average shares outstanding, to be between $(0.40) and $(0.42).

For the full-year 2019, we have updated our expectations as follows:

Total revenue to be in the range of $538 million to $545 million.
EBITDA loss to be in the range of $(39) million to $(45) million.
Adjusted EBITDA to be in the range of positive $27 million to $33 million.
Total U.S. paid membership to be in the range of 29 million to 30 million members and visit-fee-only access to be available to approximately 10 million individuals.
Total visits to be between 3.7 million to 4.0 million.
Net loss per share, based on 72.0 million weighted average shares outstanding, to be between $(1.52) and $(1.60).

Quarterly Conference Call

The second quarter 2019 earnings conference call and webcast will be held Wednesday, July 31, 2019 at 4:30 p.m. EDT. The conference call can be accessed by dialing 1-833-241-4255 for U.S. participants, or 1-647-689-4206 for international participants, and including the following Conference ID Number: 5049316 to expedite caller registration; or via a live audio webcast available online at http://ir.teladoc.com/news-and-events/events-and-presentations/. A webcast replay will be available for on-demand listening shortly after the completion of the call at the same web link.

About Teladoc Health

A mission-driven organization, Teladoc Health, Inc. is successfully transforming how people access and experience healthcare, with a focus on high quality, lower costs, and improved outcomes around the world. The company’s award-winning, integrated clinical solutions are inclusive of telehealth, expert medical services, AI and analytics, and licensable platform services. With more than 2,000 employees, the organization delivers care in 130 countries and in more than 30 languages, partnering with employers, hospitals and health systems, and insurers to transform care delivery. For more information, please visit www.teladochealth.com or follow @TeladocHealth on Twitter.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding future revenues, future earnings, future numbers of members or clients, litigation outcomes, regulatory developments, market developments, new products and growth strategies, and the effects of any of the foregoing on our future results of operations or financial conditions.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) changes in laws and regulations applicable to our business model; (ii) changes in market conditions and receptivity to our services and offerings; (iii) results of litigation; (iv) the loss of one or more key clients; and (v) changes to our abilities to recruit and retain qualified providers into our network. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our SEC reports, including, but not limited to our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as filed with the SEC.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data, unaudited)


		June 30,			December 31,
		2019			2018

Assets
Current assets:
Cash and cash equivalents	$	440,443		$	423,989
Short-term investments		32,161			54,545
Accounts receivable, net of allowance of $3,351 and $3,382, respectively		49,778			43,571
Prepaid expenses and other current assets		10,227			10,631
Total current assets		532,609			532,736
Property and equipment, net		9,722			10,148
Goodwill		748,073			737,197
Intangible assets, net		239,344			247,394
Operating lease - right-of-use assets		29,220			—
Other assets		6,376			1,401
Total assets	$	1,565,344		$	1,528,876
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	6,079		$	7,769
Accrued expenses and other current liabilities		46,201			26,801
Accrued compensation		18,141			27,869
Total current liabilities		70,421			62,439
Other liabilities		6,990			6,191
Operating lease liabilities, net of current portion		26,386			—
Deferred taxes		31,710			32,444
Convertible senior notes, net		427,197			414,683
Commitments and contingencies
Stockholders’ equity:
Common stock, $0.001 par value; 150,000,000 shares authorized as of June 30, 2019 and December 31, 2018; 71,934,381 shares and 70,516,249 shares issued and outstanding as of June 30, 2019 and December 31, 2018, respectively		72			70
Additional paid-in capital		1,483,245			1,434,780
Accumulated deficit		(468,135	)		(408,661	)
Accumulated other comprehensive (loss) income		(12,542	)		(13,070	)
Total stockholders’ equity		1,002,640			1,013,119
Total liabilities and stockholders’ equity	$	1,565,344		$	1,528,876

CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share data, unaudited)


	Quarter Ended June 30,						Six Months Ended June 30,
	2019			2018			2019			2018
Revenue	$	130,276		$	94,560		$	258,849		$	184,204
Expenses:
Cost of revenue		41,634			27,684			86,311			54,540
Operating expenses:
Advertising and marketing		26,616			19,561			53,020			39,886
Sales		15,832			14,559			32,044			28,342
Technology and development		16,665			14,348			32,652			27,252
Legal and regulatory		2,019			639			3,605			1,684
Acquisition and integration related costs		1,136			5,800			2,148			7,369
Gain on sale		—			(4,070	)		—			(4,070	)
General and administrative		38,549			26,140			74,531			50,141
Depreciation and amortization		9,848			8,046			19,448			16,299
Total expenses		152,299			112,707			303,759			221,443
Loss from operations		(22,023	)		(18,147	)		(44,910	)		(37,239	)
Interest expense, net		7,211			6,910			13,732			11,783
Net loss before taxes		(29,234	)		(25,057	)		(58,642	)		(49,022	)
Income tax (benefit) provision		90			22			832			(81	)
Net loss	$	(29,324	)	$	(25,079	)	$	(59,474	)	$	(48,941	)

Net loss per share, basic and diluted	$	(0.41	)	$	(0.40	)	$	(0.83	)	$	(0.78	)

Weighted-average shares used to compute basic and diluted net loss per share		71,721,246			62,975,535			71,322,586			62,389,902

CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands, unaudited)


	Six Months Ended June 30,
	2019			2018
Cash flows used in operating activities:
Net loss	$	(59,474	)	$	(48,941	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		22,443			16,299
Allowance for doubtful accounts		1,014			1,258
Stock-based compensation		30,891			18,891
Deferred income taxes		(1,472	)		(1,258	)
Accretion of interest		12,347			7,627
Gain on sale		—			(4,070	)
Changes in operating assets and liabilities:
Accounts receivable		(7,237	)		(4,027	)
Prepaid expenses and other current assets		1,251			(540	)
Other assets		74			(73	)
Accounts payable		374			1,371
Accrued expenses and other current liabilities		10,358			(287	)
Accrued compensation		(9,133	)		(3,812	)
Operating lease liabilities		(794	)		—
Other liabilities		(2,385	)		45
Net cash used in operating activities		(1,743	)		(17,517	)
Cash flows provided by (used in) investing activities:
Purchase of property and equipment		(1,248	)		(2,015	)
Purchase of internal-use software		(2,975	)		(1,388	)
Purchase of marketable securities		—			(12,141	)
Proceeds from marketable securities		22,695			67,970
Sale of assets		7			5,500
Investment in securities		(5,000	)		—
Acquisition of business, net of cash acquired		(11,207	)		(273,535	)
Net cash provided by (used in) investing activities		2,272			(215,609	)
Cash flows provided by financing activities:
Net proceeds from the exercise of stock options		15,701			15,765
Proceeds from issuance of convertible notes		—			279,126
Contingent consideration fair value adjustment		210			—
Proceeds from employee stock purchase plan		1,875			1,423
Cash (paid)/received for withholding taxes on stock-based compensation, net		(1,886	)		500
Net cash provided by financing activities		15,900			296,814
Net increase in cash and cash equivalents		16,429			63,688
Foreign exchange difference		25			(701	)
Cash and cash equivalents at beginning of the period		423,989			42,817
Cash and cash equivalents at end of the period	$	440,443		$	105,804

Income taxes paid	$	309		$	59

Interest paid	$	6,102		$	4,125

Non-GAAP Financial Measures:

To supplement our financial information presented in accordance with generally accepted accounting principles in the United States, or U.S. GAAP, we use EBITDA and Adjusted EBITDA, which are non-U.S. GAAP financial measures to clarify and enhance an understanding of past performance. We believe that the presentation of these financial measures enhances an investor’s understanding of our financial performance. We further believe that these financial measures are useful financial metrics to assess our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business. We use certain financial measures for business planning purposes and in measuring our performance relative to that of our competitors. We utilize Adjusted EBITDA as the primary measure of our performance.

EBITDA consists of net loss before interest, taxes, depreciation and amortization. We believe that making such adjustment provides investors meaningful information to understand our results of operations and the ability to analyze financial and business trends on a period-to-period basis.

Adjusted EBITDA consists of net loss before interest, taxes, depreciation, amortization, stock-based compensation and acquisition and integration related costs. We believe that making such adjustment provides investors meaningful information to understand our results of operations and the ability to analyze financial and business trends on a period-to-period basis.

We believe both financial measures are commonly used by investors to evaluate our performance and that of our competitors. However, our use of the term EBITDA and Adjusted EBITDA may vary from that of others in our industry. Neither EBITDA nor Adjusted EBITDA should be considered as an alternative to net loss before taxes, net loss, loss per share or any other performance measures derived in accordance with U.S. GAAP as measures of performance.

EBITDA and Adjusted EBITDA have important limitation as analytical tools and you should not consider them in isolation or as a substitute for analysis of our results as reported under U.S. GAAP. Some of these limitations are:

EBITDA and Adjusted EBITDA do not reflect the significant interest expense on our debt;
EBITDA and Adjusted EBITDA eliminate the impact of income taxes on our results of operations;
Adjusted EBITDA does not reflect the significant acquisition and integration related costs related to mergers and acquisitions;
Adjusted EBITDA does not reflect the significant non-cash stock compensation expense which should be viewed as a component of recurring operating costs; and
other companies in our industry may calculate EBITDA and Adjusted EBITDA differently than we do, limiting the usefulness of EBITDA and Adjusted EBITDA as comparative measures.

In addition, although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and EBITDA and Adjusted EBITDA do not reflect any expenditures for such replacements.

We compensate for these limitations by using EBITDA and Adjusted EBITDA along with other comparative tools, together with U.S. GAAP measurements, to assist in the evaluation of operating performance. Such U.S. GAAP measurements include net loss, net loss per share and other performance measures.

In evaluating these financial measures, you should be aware that in the future we may incur expenses similar to those eliminated in this presentation. Our presentation of EBITDA and Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by unusual or nonrecurring items.

Reconciliation of EBITDA and Adjusted EBITDA to Net Loss
(In thousands, unaudited)


	Quarter Ended						Six Months Ended
	June 30,						June 30,
	2019			2018			2019			2018
Net loss	$	(29,324	)	$	(25,079	)	$	(59,474	)	$	(48,941	)
Add:
Interest expense, net		7,211			6,910			13,732			11,783
Income tax (benefit) provision		90			22			832			(81	)
Depreciation expense		856			733			1,719			2,264
Amortization expense		8,992			7,313			17,729			14,036
EBITDA		(12,175	)		(10,101	)		(25,462	)		(20,939	)
Stock-based compensation		17,368			11,060			30,891			18,891
Amortization of warrants and loss on extinguishment of debt		—			—			—			—
Gain on sale		—			(4,070	)		—			(4,070	)
Acquisition and integration related costs		1,136			5,800			2,148			7,369
Adjusted EBITDA	$	6,329		$	2,689		$	7,577		$	1,251

Media:
Courtney McLeod
914-265-6789
cmcleod@teladochealth.com

Investors:
Westwicke Partners
Jordan E. Kohnstam
Office: 443-450-4189
Jordan.kohnstam@westwicke.com

Source: Teladoc Health, Inc.

View all Press Releases

Get in touch today

Contact Teladoc Health Investor Relations

Patrick Feeley

Vice President, Investor Relations

IR@teladochealth.com